Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes

BACKGROUND: We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden. METHODS: The Swedish Institute for Health Economics cohort model for T2D was used...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Ericsson, Åsa, Glah, Divina, Lorenzi, Maria, Jansen, Jeroen P., Fridhammar, Adam
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800677/
https://ncbi.nlm.nih.gov/pubmed/29408938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0191953
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker